GeneNews Limited, which provides innovative solutions for early cancer detection, has announced a partnership with LifeX to develop strategies for incorporating several proprietary early-cancer diagnostics into healthcare settings to improve patient compliance with cancer screening, as well as to bridge diagnostic gaps in current screening procedures.
Early detection of cancer is known to improve outcomes. Toronto-based GeneNews has several tests proven to detect cancer at an early stage using a simple blood test, or “liquid biopsy.”
“Other liquid biopsy companies are focused on monitoring response to chemotherapy or detecting recurrence of tumors after initial treatment,” said LifeX founder Dietrich Stephan.
“GeneNews, one of the pioneers of the liquid biopsy principle, has developed the ‘holy-grail’ — a suite of tests that have the correct sensitivity and specificity to see tumors in Stage 1 and perform correctly as a screening tool at the population level. We look forward to bringing these solutions to the marketplace to make a tangible difference in global health by enabling cures when tumors are most treatable.”
LifeX, based on Pittsburgh’s South Side, develops first-in-class solutions to alleviate suffering and death from prevalent and intractable diseases. The LifeX team partners with innovator-entrepreneurs to unlock the potential of their technologies and deliver them to patients and their physicians across the globe. LifeX was founded with support from the University of Pittsburgh and the Henry L. Hillman Foundation.